https://www.dermatologytimes.com/view/apg777-a-promising-breakthrough-in-il-13-targeted-therapy
0
0
10/21/23 at 7:06pm
Organization
Dermatologytimes.com
The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.
Create an account
or login to join the discussion